Objectives: To evaluate the effect of gadoxetic acid enhancement on the detection and characterisation of focal hepatic lesions on T 2 weighted and diffusion weighted (DW) images. Methods: A total of 63 consecutive patients underwent T 2 weighted and DW imaging before and after gadoxetic acid enhancement. Two blinded readers independently identified all of the focal lesions using a five-point confidence scale and characterised each lesion using a three-point scale: 1, non-solid; 2, indeterminate; and 3, solid. For both T 2 weighted and DW imaging, the accuracies for detecting focal lesions were compared using the free-response receiver operating characteristic analysis; the accuracies for lesion characterisation were compared using the McNemar test between non-enhanced and gadoxetic acid-enhanced image sets. For hepatic lesions >1 cm, the lesion-to-liver contrast-to-noise ratio (CNR) and the apparent diffusion coefficient (ADC) were compared in the non-enhanced and enhanced image sets using the generalised estimating equations. Results: For both T 2 weighted and DW images, the accuracies for detecting focal lesions (p>0.52) and those for lesion characterisation (p>0.63) did not differ significantly between the non-enhanced and enhanced image sets. The lesion-to-liver CNR was significantly higher on enhanced DW images than on non-enhanced DW images (p50.02), although the difference was not significant for T 2 weighted imaging (p50.65). The mean ADC values of lesions did not differ significantly on enhanced and non-enhanced DW imaging (p50.75). Conclusion: The acquisition of T 2 weighted and DW images after administration of gadoxetic acid has no significant effect on the detection or characterisation of focal hepatic lesions, although it improves the lesion-to-liver CNR on DW images. Various contrast agents have been developed and utilised for MRI of the liver in order to facilitate the detection and characterisation of focal hepatic lesions. Gadoxetic acid (gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid, PrimovistH; Bayer Schering Pharma, Berlin, Germany) is a recently developed, liverspecific contrast agent. As it has combined extracellular and hepatocyte-specific properties, gadoxetic acid can provide functional information regarding the cellular composition of focal hepatic lesions on hepatobiliary phase imaging as well as haemodynamic information on dynamic MRI following bolus injection. These properties of gadoxetic acid have been reported to improve the accuracy of liver MRI for lesion detection and characterisation [1][2][3][4][5][6][7].By contrast, these advantages of gadoxetic acidenhanced liver MRI are obtained with increased examination time, as delayed scanning approximately 20 min after contrast administration is necessary for optimal hepatobiliary phase imaging [4,5,[7][8][9]. Among the pulse sequences commonly acquired for clinical liver MRI, T 2 weighted and diffusion weighted (DW) imaging are frequently performed using a respiratory-triggered method in order to improve image quality...